Drug intelligence / Profile preview

orelabrutinib + rituximab + methotrexate

Development stage: Unknown
Lead developer: InnoCare Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal

Overview

This is a combination therapy consisting of orelabrutinib (a BTK inhibitor), rituximab (an anti-CD20 monoclonal antibody), and methotrexate (an antimetabolite and antifolate drug). While rituximab + methotrexate combinations have been studied in conditions like rheumatoid arthritis and primary central nervous lymphoma, there is no specific information in the search results about the triple combination with orelabrutinib.

Other names: Orelabrutinib, Rituximab, and Methotrexate

Targets

BTK (Bruton tyrosine kinase)DHFR (Dihydrofolate reductase)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on orelabrutinib + rituximab + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on orelabrutinib + rituximab + methotrexate.

Explore the full profile